European Medicines Agency validates Pierre Fabre Laboratories’ marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC)

– BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC – The application is based on results from the PHAROS study,[1] which showed an objective response rate of 75% in treatment-naïve patients and 46% in…